Results from First-of-Kind Abilify Maintena Study Announced

Results from First-of-Kind Abilify Maintena Study Announced
Results from First-of-Kind Abilify Maintena Study Announced

Otsuka and Lundbeck announced results from the first-of-its-kind study comparing the effectiveness of aripiprazole extended-release injectable suspension (Abilify Maintena) and paliperidone palmitate extended-release injectable suspension (Invega Sustenna; Janssen) in adults patients with schizophrenia.

In the 28-week, randomized, open-label, rater-blinded QUALIFY study, patients received either intramuscular aripiprazole once-monthly (400mg or 300mg/month) or intramuscular paliperidone palmitate (78–234mg/month). The intramuscular formulations were administered following a 3-week oral conversion period when patients received either oral aripiprazole or oral paliperidone. Patients treated with aripiprazole once-monthly showed a statistically significant and superior improvement in the Heinrichs-Carpenter Quality of Life Scale (QLS) total score vs. those treated with paliperidone palmitate. From baseline to Week 28, the mean change in QLS total score was 7.5 for the aripiprazole arm and 3.1 for the paliperidone palmitate group.

RELATED: FDA Approves New Formulation for Abilify Maintena

Abilify Maintena is an intramuscular injection indicated for the treatment of schizophrenia. The mechanism of action of aripiprazole, an atypical antipsychotic, in the treatment of schizophrenia is unknown. However, the efficacy of aripiprazole may be mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors.

For more information call (800) 438-9927 or visit AbilifyMaintena.com.